Introduction
============

Acute Leukemia is the most common pediatric cancer ^[@B1],[@B2]^ . Despite numerous efforts focused on leukemia treatment, this type of disease remains one of the greatest challenges in pediatric oncology[@B3]. Current therapeutic strategies are unable to provide long-term remission for 20% of children with ALL (25-40% cure rate after relapse)[@B4]. Some subgroups of infants are likely to be over treated and might be healed using less intensive regimens which results in reduced toxicity and fewer long-term side effects ^[@B5]-[@B7]^ . Response to treatments is variable depending on different clinical, immunological, cytogenetic/genetic characteristics and environmental exposures, which are associated with increased risk of leukemia and their diverse response to treatment ^[@B8]-[@B12].^

One of the mentioned genetic factors is Heme Oxygenase-1 gene (*HO-1*), located on chromosome 22. This gene produces an essential enzyme in heme catabolism. It has 2 isozymes, an inducible heme oxygenase-1 and a constitutive heme oxygenase-2^[@B13]^. *HMOX1* and *HMOX2* belong to the heme oxygenase family. Heme Oxygenase (*HO*) gene encodes an enzyme which catalyzes the first and rate-limiting steps in oxidative degradation of heme to the form of open-chain tetrapyrrole biliverdin-IX with final release of carbon dioxide, biliverdin and free iron . By now, three isozymes of mammalian *HO* have been identified, in which *HO-1* variant is the only inducible isozyme with expression in different normal and neoplastic cells. *HO-1* expression in malignant tissues is higher than its surrounding healthy tissues which could be up regulated by different stimuli and oxidative stresses such as radiotherapy, chemotherapy and photodynamic therapies ^[@B14]-[@B20]^ .

*HO-1* is involved in pathogenesis of acute leukemia patients and their resistance to treatment ^[@B8]-[@B11]^ . Expression of HO-1 has the protective and anti-apoptotic effects through its active biological products*.* ^[@B21],[@B22]^ . As a result, it\'s possible that the upregulation of HO-1 is responsible for increasing tumor resistance to chemotherapy or radiotherapy. ^[@B23],[@B24]^ . However, *HO-1* expression level is dependent to its polymorphisms and fluctuates between individuals, quantitatively ^[@B25],[@B26]^ .

GT repeats in *HO-1* gene promoter modulate transcription of *HO-1* gene. The dinucleotide sequence can adversely affect the basal promoter activity ^[@B27]-[@B30]^ . GT repeats ranged between 12 - 40 base pairs. This range can be divided into short "S" and long "L" alleles although there is not an exact cut-off to separate two alleles^[@B16],[@B31],[@B32]^. Moreover, some surveys revealed higher prevalence of \"S\" allele in renal cell carcinoma, pancreatic cancer, gastric cancer and gastric adenocarcinoma^[@B33]^. Paradoxically, patients with squamous cell carcinoma and lung adenocarcinoma often carry "L" allele^[@B16],[@B31],[@B34]-[@B37]^. Some studies revealed that *HO-1*targeting with either pegylated zinc protoporphyrin (PEG-ZnPP) or styrene maleicacid-micelle--encapsulated ZnPP (SMAZnPP) results in growth inhibition in cancer cells with subsequent increased sensitivity to radiotherapy and chemotherapy ^[@B22],[@B38]-[@B40]^ .

Despite advent of novel strategies for treatment of acute leukemia, resistance to treatment is the greatest concern until now. *HO-1* over expression provides cytoprotective and antiapoptotic effects on malignant cells against radiotherapy and chemotherapy. Although the role of *HO-1* in AML and CML cell lines has been studied, the distribution of allele frequency in leukemia and its association with resistance to treatment and survival remains unveiled^[@B10]^. This study was designed to compare the allelic frequencies of genetic variants in the promoter of HO-1 among patients suffering from acute leukemia compared with healthy controls. The relationship between GT repeats and patient's 3-year and 5-year survival was also assessed.

MATERIALS AND METHODS
=====================

**Patient selection**

This is a controlled, cross-sectional study that included 63 patients with acute leukemia admitted to Seyed-al-Shohada Hospital, Isfahan from 2006 to 2009. The control group consisted of 54 gender and age-matched healthy children. Our data about survival after chemotherapy and bone graft were gathered from patients' medical records. DNA was extracted from bone marrow samples of the patients. Genomic DNA was extracted through QIAamp DNA blood mini kit (QIAGEN, USA) according to the manufacturer's instruction. The study protocol was approved by the Ethics Board of Isfahan University of Medical Sciences

**Heme oxygenase-1 genotyping**

The *HO-1* microsatellite was amplified through PCR using a 5\'-FAM-labeled forward primer (AGAGCCTGCAGCTTCTCAGA) and a 3\'-unlabelled reverse primer (GTCCTATGGCCAGACTTTGT), in 30 cycles (94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 30 seconds) and final extension at 72°C for 5 minutes by thermo cycler (Eppendorf Mastercycler EP Gradient, USA). Labeled PCR products were compared with a standard size marker GenoType^TM^ TAMRA DNA ladder (size range 50--500 bp) (Gibco-BRL, Paisley, Scotland, UK). Number of GT repeats was determined with an ABI 3100 sequencer (Applied Biosystems, USA), using GeneMarker V1.97 software (Softgenetics, USA). Selected samples were sequenced by ABI 3100 sequencer (Applied Biosystems, USA).

**Statistical** **analysis**

Statistical analyses were performed using SPSS 16.0. Chi-square test was used for categorical variables. Three-year survival was compared with allelic frequencies of *HO-1* polymorphism. Differences in alleli c frequency of *HO-1* promoter were compared between leukemia patients and controls. Difference of data with *P*\< 0.05 was considered as a significant.

Results
=======

Demographic characteristics of patients including age and sex are shown in [Table 1](#T1){ref-type="table"}. Frequency distribution of age and sex was not significantly different between studied groups. Patients whose data were incomplete were excluded from the study.

###### 

Demographic characteristics of patients (age and sex)

  **Group**                  **Case**     **control**   **P-value**   
  ---------------------- --- ------------ ------------- ------------- --------
  Age (years) Mean ±SD       5.93 ±0.63   4.87±0.26     \>0.05        
  Gender (%)             F                59.5          46.2          \>0.05
  M                          40.5         53.8                        

The *HO-1* genotyping process for 63 cases and 54 healthy controls was performed successfully. The alleles frequency of (GT)~n~ microsatellite polymorphism of HO -1 gene promoter was found in both case and control groups ([Figures 1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}). The GT repeat numbers ranged from 14 to 34, and the most prevalent allele in our population was (GT)~27~. Therefore, we divided these alleles into two subgroups. (GT)~n~ : short (S) alleles \<27 repeats and long (L) alleles ≥27 repeats. Three genotypes (SS, SL and LL) were created for the study population. The subjects with genotype SS and SL were placed in a group identified as \"short carrier genotype\" and those with LL genotype were placed in a group identified as \"long genotype\".

![Frequency distributions of (GT) repeats in all participants (n=117)](IJHOSCR-12-49-g001){#F1}

![Frequency distributions of (GT) repeats in leukemia patient (n=56)](IJHOSCR-12-49-g002){#F2}

![Frequency distributions of (GT) repeats in control group (n=61)](IJHOSCR-12-49-g003){#F3}

There was no significant difference in the frequency of genotypes between leukemia patients and controls (P= 0.629) ([Table 2](#T2){ref-type="table"}). The \"long genotype\" was more frequent in leukemia patients with better vs. worse 3-year surveillance (*P*\< 0.05)([Table 3](#T3){ref-type="table"}). Furthermore, there was no significant difference in hepatomegaly, splenomegaly and CSF metastasis in two genotype groups (P≥0.05) ([Table 4](#T4){ref-type="table"}).

###### 

Genotype[\*](#TFN1){ref-type="table-fn"} distribution in case and control groups

            **Genotypes**   **P-value**           
  --------- --------------- ------------- ------- -------
            LL              LS            SS      0.629
  Case      33.3%           47.6%         19%     
  Control   33.3%           40.7%         25.9%   

(GT)n \< 27 Repeats: S allele, (GT)n ≥ 27 Repeats: L allele, SS: Homozygote for Short Allele, LL: Homozygote for Long Allele, LS: Heterozygote Person

###### 

Genotype\* distribution for leukemia patients according to 3-and 5-year survival, respectively

                               **Genotype**           **P-value**
  ---------------------- ----- -------------- ------- -------------
                               S carrier      LL      
  3-year survival rate                                
                         Yes   38.8%          30.5%   0.043
                         No    27.7%          2.7%    
  5-year survival rate                                
                         Yes   39.3%          21.2%   0.371
                         No    30.3%          9.0%    

(GT)n \< 27 Repeats: S allele, (GT)n ≥ 27 Repeats: L allele, SS: Homozygote for Short Allele, LL: Homozygote for Long Allele, LS: Heterozygote Person

###### 

Genotype\* distribution of leukemic regarding hepatomegaly, splenomegaly and CSF metastasis

  -------------------------------------------------------------
                          **Genotypes**   **P-value**   
  ---------------- ------ --------------- ------------- -------
                          S carrier       LL            

  Hepatomegaly     (+)\   21.0%\          15.85\        0.142
                   (-)    50.0%           13.1%         

  Splenomegaly     (+)\   40.5%\          16.2%\        0.571
                   (-)    29.7%           13.5%         

  CSF Metastasis   (+)\   2.9%\           0.0%\         0.706
                   (-)    67.6%           29.4%         
  -------------------------------------------------------------

S carrier: a person who is carrier for S allele, LL: Homozygote for L allele, CSF Metastasis: Metastasis to Cerebrospinal fluids (CSF)

Discussion
==========

In this study, we investigated polymorphic (GT)~n~ repeats in *HO-1* promoter region in patients suffering from leukemia. In addition, we investigated the association between allelic frequency and patients' 3-year surveillance. We found no relationship between frequency distribution of (GT)~n~ repeats and leukemia incidence. We have observed that patients carrying "LL" allele had significantly better 3-year survival. Five-year survival was slightly better in carriers of "LL" allele although this difference was not statistically significant. Moreover, we studied genotype distribution among patients considering hepatomegaly, splenomegaly and CSF metastasis ([Table 4](#T4){ref-type="table"}), which revealed no relationship between (GT)n repeats in *HO-1* promoter and clinical features of patients.

HO-1 gene is induced in response to oxidative stress such as chemotherapy and radiotherapy^[@B41]^. The basal and induced levels of HO-1 gene expression are different in each individual. The polymorphism length of *HO-1,* influences the level of gene transcription. Excessive GT repeats reduced promoter activity, while short GT alleles led to higher levels of *HO-1* expression with further anti-apoptotic effects. Our results suggest that "SS" and "SL" genotypes make tumors more resistant to anticancer therapy in acute leukemia.

*HO-1* considered as a "friend" which supports normal tissues against carcinogen-induced invasion ^[@B42],[@B43]^ Nevertheless, during the neoplastic development, *HO-1* turns into a "false friend" and facilitate tumor development. *HO-1* over expression in CML tumor cells increases its viability through apoptosis inhibition.

Meyerhof et al. have treated CML cells by zinc-(II)-deuteroporphyrin-IX, inhibitor of HO-1 and hemin, inducer of an HO-1. Parallel usage of HO-1 inhibitors and inducers, decreases and increases CML cells viability in stress oxidative environment, respectively. Also, it has been apparent that HO-1 reduces sensitivity of cancer cells to chemotherapy and radiotherapy^[@B22],[@B44]^.

The length polymorphism of GT repeats in *HO-1* gene promoter had various impacts in different disease states. Chang et al*.* reported an increased risk of oral squamous cell carcinoma in patients with more than 31 GT-repeats^[@B45]^. Moreover, some surveys revealed a higher frequency of \"S\" allele in renal cell carcinoma, pancreatic cancer, gastric cancer, gastric adenocarcinoma, lymphoma and Kaposi sarcoma. In this study, the frequency of "S" alleles and "L" alleles were equal in both leukemia patients and control groups.

This study is the first to investigate *HO-1* gene promoter polymorphism and surveillance (3 years) in leukemia patients. Although we found no significant differences between leukemia patients and control groups regarding short (GT) n repeat alleles in *HO-1* promoter, higher frequency of "LL" genotype in leukemia patients with positive 3-year surveillance was found. Indeed, LL genotype in leukemia patients was associated with slightly better 5-year surveillance.

Oxidative stress conditions such as radiotherapy and chemotherapy lead to additional expression of *HO-1* gene^[@B41]^. These data supports the idea that higher levels of *HO-1* gene expression, associated with "SS" and "SL" genotype, might play an important role in elevated resistance of leukemia patients to chemotherapy or radiotherapy.

CONCLUSION
==========

Modification of *HO-1* expression level might have positive effect on the prognosis of leukemia patients under treatment. Further studies are required to determine the impact of *HO-1* genotype in patients with acute leukemia.
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